Related Experiment Video
Updated: Sep 8, 2025
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.7K
Effect of Statin Therapy on Clinical Outcomes in Patients With Cardiovascular Risks: A Systematic Review and
Kiyan Ghani Khan1, Priyadeep Kaur2, Mehak Bhagat3
1Internal Medicine, Baqai Medical University, Karachi, PAK.
Cureus
|August 20, 2025
Summary
Statin therapy significantly reduces all-cause mortality and major adverse cardiovascular events (MACE). However, its impact on cardiovascular mortality and hospitalizations requires further study, highlighting the need for complementary risk management strategies.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Statins are primary agents for lowering low-density lipoprotein (LDL) cholesterol.
- Effective LDL reduction mitigates atherosclerosis and cardiovascular (CV) event risk.
- Adults with CV risk factors or established cardiovascular disease (CVD) are key populations.
Purpose of the Study:
- To systematically review and meta-analyze the impact of statin therapy on mortality and major adverse cardiovascular events (MACE).
- To assess statins' effects on all-cause mortality, CV mortality, MACE (heart attack, stroke, revascularization), and CV hospitalization.
- To evaluate statin efficacy in adults with or at risk for CVD.
Main Methods:
- Systematic literature search of PubMed, Google Scholar, and Cochrane Central (2013-2024).
- Inclusion of randomized controlled trials, prospective cohorts, and retrospective studies.
- Random-effects model meta-analysis with heterogeneity assessment (I² statistic).
Main Results:
- Seven studies (506,813 patients) showed statins significantly reduced all-cause mortality (RR 0.60) and MACE (RR 0.75).
- High heterogeneity noted for mortality outcomes, suggesting variations in study populations and statin types.
- Non-significant trends for CV mortality (RR 0.74) and no significant reduction in CV hospitalizations (RR 0.97) were observed.
Conclusions:
- Statin therapy is confirmed to significantly lower all-cause mortality and MACE, supporting its role in CV risk reduction.
- The effect of statins on CV mortality and CV hospitalization requires further investigation.
- Complementary strategies may be necessary to further reduce hospital admissions in statin-treated patients.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
863
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
863
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
3.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.1K
01:30Coronary Artery Disease III: Clinical Manifestations
31
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
31
01:27Coronary Artery Disease V: Interprofessional Care
30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
173
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
173